期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向药物在晚期肾癌中的个体化应用

原文传递
导出
摘要 随着靶向药物研究的深入发展，靶向治疗在晚期肾癌中的应用更加广泛。本文就晚期肾癌患者的组织学类型、临床特征、药物的毒副反应、生物标记物等，综述靶向药物在晚期肾癌中的个体化应用。
作者 罗成君 苟欣
机构地区 重庆医科大学附属第一医院泌尿外科
出处 《国际泌尿系统杂志》 2015年第3期424-427,共4页 International Journal of Urology and Nephrology
关键词 肾肿瘤 癌 肾细胞
分类号 R737.11 [医药卫生—肿瘤]
作者简介 通讯作者：罗成君Email：luochengjun07@163．com
  • 相关文献

参考文献30

  • 1Gupta K, Miller JD, Li JZ, et al. Epidemiological and socioeconomic burden of metastatic renal cell carcinoma: a literature review [ J]. Cancer Treat Rev ,2008,34 : 193 - 205.
  • 2Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for pa- tients with localized renal cell carcinomas [ J ]. Clin Cancer Res, 2008,14 : 5579 - 5584.
  • 3Eble JN, Sauter G, Epstein JI, et al. World health organization clas- sification of tumours [ M ]. Lyon, France : IARC Press; 2004. Pa- thology and genetics of tumours of the genitourinary system and male genital organs.
  • 4Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo controlled randomised discontinuation trial of sorafenib ( BAY 43 - 9006) in patients with advanced renal cell cancer[ J]. Proc Am Soc Clin Oncol, 2005, 23: 388S.
  • 5Motzer R J, Rini BI, Michaelson MD, et al. Phase 2 trials of SU 11248 show antitumor activity in second - line therapy for patients with metastatic renal cell carcinoma (RCC) [ J]. Proc Am Soc Clin 0ncol,2005,23:4508.
  • 6Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everoli- mus for metastatic renal cell carcinoma : Final results and analysis of prognostic factors [ J ]. Cancer,2010,116 ( 18 ) :4256 - 4265.
  • 7Rini BI, Escndier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma ( ax- is) : A randomised phase 3 trial [ J ]. Lancet,2011. Cohen HT, McGovern FJ. Renal - cell carcinoma [ J ]. N Engl J Med,2005,353 (23) :2477 - 2490.
  • 8Cohen HT, McGovern FJ. Renal - cell carcinoma [ J ]. N Engl J Med,2005,353 (23) :2477 - 2490.
  • 9Srinivasan R, Choueiri TK, Vaishampayan U. A phase ii study of the dual met/vegfr2 inhibitor x1880 in patients (pts) with papillary renal carcinoma(pro) [ J ]. J Clin Oneo1,2008 ,26 :5103.
  • 10Sfinivasan R, Linehan WM, Vaishampayan U. A phase ii study of two dosing regimens of gsk 1363089 (gsk089) , a dual met/vegfr2 inhibitor, in patients ( pts ) with papillary renal carcinoma (prc ) [ J]. J Clin Oncol,2009,27:5103.

二级参考文献35

  • 1Krause,DS,Van,Etten,RA,黄艳.癌症治疗的靶点——酪氨酸激酶[J].中国处方药,2005(10):33-36. 被引量：45
  • 2Moizer R J . Mazumdar M, Bacik J, el al. Survival andprognostic stratification of 670 patients with advancedrenal cell carcinoma [J]. J Clin Oncol, 1999, 17 ( 8):2530一 2540.
  • 3Belldegrun A S. Klatte T, Shuch 13,et al. Cancer-spe-cific survival outeomcs among patients treated duringthe cytokine era of kidney cancer ( 1989-2005 ) : abenchmark for emerging targeted cancer therapies [J].C ancer. 2O08. 113(9) : 2157一2463.
  • 4Escudier B, Eisen T. Stadler W M, et al. Sorafenib fortreatment of renal cell carcinoma : Final cfficacy andsafety results of the phase III treatment approaches inrenal cancer global evaluation trial [J]. J Clin Oncol.2009. 27(20): ;312-3318.
  • 5Kscudit'r D, Pluzanska A,Koralewski P. et al. Bevaci-zumab plus interferon alfa-2a for treatment of meiastat-ic renal cell carcinoma: a randomised, double-blindphase III trial[J]. Lancet, 2007,370 ( 9605 ) : 2103 -2111.
  • 6Moizer R J, Escudier B. Oudard S, ct al. Efficacy ofeverolinius in advanced renal cell carcinoma : a double-blind .randomised. placebo controlled phase III trial[J]. Uiu’el, 2008, 372(9637) : 449 -.156.
  • 7Motzer R J, Hutson T E. Tomczak P. ct al. Overallsurvival and updated roNulls for sunitinib comparedwith inierferon alfa in patients with metastatic renal cellcarcinoma[J J. J Clin Oncol, 2009 . 27 ( 22 ) : 308-1 --3590.
  • 8vSuarez C'. Morales R. Munoz E,et al. Molecular basisfor the treatment of renal cell carcinoma [ J ]. ClinTransl Oncol. 2010,12(1) : 15 - 21.
  • 9Mendel D B, Laird A D, Xin X,et al. In vivo antitu-mor activity of SU11248 , a novel tyrosine kinase inhib-itor targeting vascular endothelial growth factor andplatelet-derived growth factor receptors : determinationof a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003,9(1): 327 - 337.
  • 10Ferrara N. Hillan K J, Gerber H P. et al. Discoveryand development of bevacizumab. an anti-VEGF anti-body for treating cancer [J]. Nat Rev Drug Discov.2004, 3(5) : 391 -400.

共引文献20

国际泌尿系统杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部